CBPL

Chandra Bhagat Pharma financials

Market cap
₹25 Cr

Quarterly results

Q4 FY26: revenue down 10.8%, net profit up 200.0% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY23Q4 FY23Q2 FY24Q4 FY24Q2 FY25Q4 FY25Q2 FY26Q4 FY26
Revenue44 75 119 102 65 +48%22 −71%26 −78%91 −11%
EBITDA1 2 -5 -2 -1 −200%0 −100%2 +140%2 +200%
Net profit0 1 1 1 1 0 −100%0 −100%3 +200%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −7.0% 1Y

₹30.0₹35.0₹40.0₹45.0₹50.0Sept 25Nov 25Dec 25Feb 26Apr 26May 26Jul 26Aug 26

1Y: ₹48 on 8 Sept 2025 → ₹44.65. High ₹52.5 (13 Aug 2026), low ₹29.95 (27 Mar 2026).

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹8 Cr₹8 Cr
Reserves₹18 Cr₹19 Cr₹20 Cr₹21 Cr₹23 Cr₹26 Cr
Borrowings₹27 Cr₹21 Cr₹19 Cr₹16 Cr₹21 Cr₹17 Cr
Other liabilities₹19 Cr₹25 Cr₹14 Cr₹56 Cr₹37 Cr₹45 Cr
Total liabilities₹72 Cr₹72 Cr₹61 Cr₹102 Cr₹88 Cr₹94 Cr
Fixed assets₹0 Cr₹0 Cr₹1 Cr₹3 Cr₹2 Cr₹3 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Investments₹0 Cr₹0 Cr₹0 Cr₹0 Cr₹1 Cr₹2 Cr
Other assets₹71 Cr₹72 Cr₹60 Cr₹99 Cr₹85 Cr₹90 Cr
Total assets₹72 Cr₹72 Cr₹61 Cr₹102 Cr₹88 Cr₹94 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Mar 2026

Since Mar 2025, promoters added +1.82 pp while the public trimmed −1.19 pp. The shareholder count shrank 11% to 280.

Promoters
73.0%
Public
27.0%

Since Mar 2025

  • Promoters +1.82 pp
  • Public −1.19 pp
  • FIIs −0.61 pp

How it drifted, 12 quarters

Over this window promoters went from 70.4% to 73.0% — +2.6 pp.

Sep '20Mar '23Mar '26

Ownership split by quarter, oldest first. Sep '20: Promoters 70.4%, Public 29.6%.Mar '21: Promoters 71.8%, Public 28.2%.Sep '21: Promoters 71.8%, Public 28.2%.Mar '22: Promoters 70.1%, Public 29.9%.Sep '22: Promoters 69.1%, FIIs 0.8%, Public 30.1%.Mar '23: Promoters 68.2%, FIIs 0.8%, Public 30.9%.Sep '23: Promoters 68.7%, FIIs 1.3%, DIIs 0.9%, Public 29.1%.Mar '24: Promoters 68.8%, FIIs 1.3%, DIIs 0.9%, Public 29.0%.Sep '24: Promoters 69.3%, FIIs 0.5%, Public 30.2%.Mar '25: Promoters 71.2%, FIIs 0.6%, Public 28.2%.Sep '25: Promoters 72.2%, FIIs 0.6%, Public 27.2%.Mar '26: Promoters 73.0%, Public 27.0%.

Who was buying across the market this quarter →

Who bought this quarter

since Sep 2025

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.

Who is on the register

Named in the Mar 2026 filing

Every holder of Chandra Bhagat Pharma Limited above SEBI's 1% disclosure line, and what changed since Sep 2025.

HolderStakeChange
Hemant Chandravadan Bhagat 35.50%unchanged
Chitra Hemant Bhagat 16.34%unchanged
Pranav Hemant Bhagat 10.10%unchanged
Team Anamika Algo Limited 7.94%unchanged
Prachi Pranav Bhagat 5.35%+0.82 pp
Hemant C Bhagat Huf 1.97%unchanged
Prashant A Thakkar Huf 1.64%newly disclosed
Mahesh C Bhagat 1.59%unchanged
Riddhi Abhinav Chheda 1.56%unchanged
Multiply Finvest Private Limited 1.14%unchanged
First Rate Investments Private Limited 1.13%unchanged
Jay Hemant Bhagat 1.11%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Learn to analyse Chandra Bhagat Pharma Limited

Guides on how to read this kind of business and the numbers that matter.